Gesynta Pharma AB
Pharmaceuticals - Stockholm, Stockholm County, Sweden
Gesynta Pharma AB Employees
Gesynta Pharma AB Details
Founded in 2017, Gesynta Pharma bases its R&D on research from the Karolinska Institutet. The company's most advanced drug candidate, GS-248, reduces inflammation and increases blood flow in the microvasculature, thereby having the potential to provide improved treatments for several serious diseases. In an ongoing clinical proof-of-concept study, GS-248 is being evaluated for its capacity to normalize vascular blood flow and reduce pain in patients with the autoimmune disease systemic sclerosis. Positive results from this study may lead to a rapid broadening of the development program towards additional chronic inflammatory diseases.Major shareholders include Industrifonden, Linc, Hadean Ventures, and a number of successful life science entrepreneurs.
Gesynta Pharma AB Technologies
Email Providers
Outlook
Tag Management
Google Tag Manager
Other
Mobile Friendly
CSS and JavaScript Libraries
Bootstrap Framework